These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28092987)

  • 1. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Myeloma Bone Lesions.
    Du JS; Yen CH; Hsu CM; Hsiao HH
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
    Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
    Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
    Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma bone disease: pathogenesis and treatment.
    O'Donnell EK; Raje NS
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):285-295. PubMed ID: 28591104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of bone disease in multiple myeloma.
    Terpos E; Berenson J; Raje N; Roodman GD
    Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of multiple myeloma-related bone disease].
    Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; Małecki K; Skotnicki AB
    Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
    Kleber M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2019 Aug; 12(8):651-663. PubMed ID: 31268745
    [No Abstract]   [Full Text] [Related]  

  • 18. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
    Criscitiello C; Viale G; Gelao L; Esposito A; De Laurentiis M; De Placido S; Santangelo M; Goldhirsch A; Curigliano G
    Cancer Treat Rev; 2015 Feb; 41(2):61-8. PubMed ID: 25499997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.